“We are very pleased to back Kuano in this venture. Being able to more accurately understand and predict subtle changes around enzyme’s active sites could unlock faster opportunities to push inhibitors for difficult drug targets through discovery and development.” Sunil Shah, CEO o2h

InnovateUK has awarded Kuano a “Business-led innovation in response to global disruption grant to build a combined AI and modelling service for rapid response drug design.

Kuano has been selected to join the COVID-19 High Performance Computing (HPC) Consortium and will work with AWS to identify novel COVID-19 drugs using a combination of virtual screening and machine learning approaches.

We are excited to have become an SME member of CrowdHelix, a EU and UK focussed community of over 4030 SMEs and research & innovation professionals working together to enable collaborations and partnerships.

Kuano has joined CompBioMed, a European HPC Centre of Excellence as an associate partner. CompBioMed brings together leading academic institutions (including UCL, University of Oxford and University of Edinburgh in the UK), leading HPC centres across Europe and industry partners such as Janssen, AstraZeneca and GSK.